CO2020013690A2 - Composiciones y métodos para el tratamiento de la distrofia macular - Google Patents

Composiciones y métodos para el tratamiento de la distrofia macular

Info

Publication number
CO2020013690A2
CO2020013690A2 CONC2020/0013690A CO2020013690A CO2020013690A2 CO 2020013690 A2 CO2020013690 A2 CO 2020013690A2 CO 2020013690 A CO2020013690 A CO 2020013690A CO 2020013690 A2 CO2020013690 A2 CO 2020013690A2
Authority
CO
Colombia
Prior art keywords
macular dystrophy
compositions
treatment
methods
subject
Prior art date
Application number
CONC2020/0013690A
Other languages
English (en)
Spanish (es)
Inventor
De La Camara Cristina Martinez-Fernandez
Robert Maclaren
Gregory S Robinson
Original Assignee
Univ Oxford Innovation Ltd
Nightstarx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, Nightstarx Ltd filed Critical Univ Oxford Innovation Ltd
Publication of CO2020013690A2 publication Critical patent/CO2020013690A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CONC2020/0013690A 2018-04-05 2020-10-30 Composiciones y métodos para el tratamiento de la distrofia macular CO2020013690A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05
PCT/US2019/026062 WO2019195727A1 (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Publications (1)

Publication Number Publication Date
CO2020013690A2 true CO2020013690A2 (es) 2021-04-19

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013690A CO2020013690A2 (es) 2018-04-05 2020-10-30 Composiciones y métodos para el tratamiento de la distrofia macular

Country Status (21)

Country Link
US (2) US20190307900A1 (https=)
EP (1) EP3775233A1 (https=)
JP (1) JP2021520232A (https=)
KR (1) KR20210005040A (https=)
CN (1) CN113056561A (https=)
AU (1) AU2019247864A1 (https=)
BR (1) BR112020020204A2 (https=)
CA (1) CA3096088A1 (https=)
CL (1) CL2020002561A1 (https=)
CO (1) CO2020013690A2 (https=)
EA (1) EA202092069A1 (https=)
IL (1) IL277779A (https=)
JO (1) JOP20200253A1 (https=)
MA (1) MA52199A (https=)
MX (1) MX2020010477A (https=)
PE (1) PE20210918A1 (https=)
PH (1) PH12020551641A1 (https=)
RU (1) RU2020132890A (https=)
SG (1) SG11202009759SA (https=)
TW (1) TW202003052A (https=)
WO (1) WO2019195727A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870148A4 (en) * 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
US20220089670A1 (en) * 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
US20230112568A1 (en) * 2020-02-28 2023-04-13 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
EP4590841A2 (en) * 2022-09-20 2025-07-30 Aldevron, LLC Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2307551T3 (pl) * 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EP3071592B1 (en) * 2013-11-20 2021-01-06 Fondazione Telethon Artificial dna-binding proteins and uses thereof
AU2014359136B2 (en) * 2013-12-06 2020-06-25 Centre Hospitalier Universitaire De Montpellier Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
RS63416B1 (sr) * 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
WO2017083722A1 (en) * 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy

Also Published As

Publication number Publication date
KR20210005040A (ko) 2021-01-13
PE20210918A1 (es) 2021-05-19
EA202092069A1 (ru) 2021-03-12
MA52199A (fr) 2021-02-17
MX2020010477A (es) 2021-03-02
US20230149566A1 (en) 2023-05-18
JP2021520232A (ja) 2021-08-19
CN113056561A (zh) 2021-06-29
JOP20200253A1 (ar) 2020-10-04
CA3096088A1 (en) 2019-10-10
IL277779A (en) 2020-11-30
PH12020551641A1 (en) 2021-07-26
RU2020132890A (ru) 2022-05-06
BR112020020204A2 (pt) 2021-01-19
CL2020002561A1 (es) 2021-04-23
AU2019247864A1 (en) 2020-10-22
US20190307900A1 (en) 2019-10-10
EP3775233A1 (en) 2021-02-17
SG11202009759SA (en) 2020-10-29
WO2019195727A1 (en) 2019-10-10
TW202003052A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CO2020013690A2 (es) Composiciones y métodos para el tratamiento de la distrofia macular
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
MX2021012862A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CO2019008684A2 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer
MX2021009673A (es) Moduladores de ror-gamma.
UY37997A (es) Agentes antivirales contra la hepatitis b
PH12020550051B1 (en) Glp-1 compositions and uses thereof
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
MX373692B (es) Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2017016610A (es) Metodos de reduccion de olor.
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
AU2017256910A1 (en) Optogenetic visual restoration using Chrimson
MX384321B (es) Composición para administración oral de agentes bioactivos.
MX420767B (es) Proteina de union al factor h modificada
NZ751983A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CO2021003136A2 (es) Terapias de combinación